Literature DB >> 2935548

Determination of midazolam (Versed) and its metabolites in plasma by high-performance liquid chromatography.

C V Puglisi, J Pao, F J Ferrara, J A de Silva.   

Abstract

A rapid, sensitive and selective high-performance liquid chromatographic (HPLC) assay was developed for the determination of midazolam, 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]- benzodiazepine (I), and its four metabolites in plasma. The assay involves extraction into diethyl ether--methylene chloride (7:3) from plasma buffered to pH 9 and subsequent analysis by reversed-phase HPLC with ultraviolet detection at 254 nm. The overall recovery of I from dog plasma was 94.5 +/- 7.1% and greater than 89.0% for its metabolites. The sensitivity limit of the assay was 50 ng/ml of plasma for all compounds. The HPLC assay was used to determine plasma concentrations of I and its metabolites from selected samples taken from an oral toxicity study in the dog.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2935548     DOI: 10.1016/s0378-4347(00)82020-4

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Pharmacokinetics of midazolam during continuous infusion in critically ill neonates.

Authors:  E Jacqz-Aigrain; P Daoud; P Burtin; S Maherzi; F Beaufils
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Pharmacokinetics of midazolam in critically ill neonates.

Authors:  E Jacqz-Aigrain; C Wood; I Robieux
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Development of midazolam sublingual tablets: in vitro study.

Authors:  P Odou; C Barthelemy; H Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.